Assessing Treatment Benefit in Immuno-Oncology

September 25, 2018

Free Live Webinar: Assessing Treatment Benefit in Immuno-Oncology

In this webinar we reviewed key issues related to endpoints in immuno-oncology, with a brief overview of the four different sets of criteria  for response assessment in immunotherapy. Then we reviewed the novel approaches both for the design and analysis of clinical trials, including the assessment of the net benefit through the use of generalized pairwise comparison (GPC).

CLICK HERE TO VIEW THE RECORDED WEBINAR

KEY LEARNING OBJECTIVES: 

In this webinar, featured speakers :

  • Reviewed key issues in the recent literature related to endpoints in immuno-oncology, with a brief overview of the four different sets of criteria that have been proposed for response assessment in immunotherapy
  • Used examples from the recent literature to illustrate the limitations of current statistical methods in the assessment of progression-free survival and overall survival,
  • Reviewed the novel approaches that have been proposed both for the design and analysis of clinical trials, including the assessment of the net benefit through the use of generalized pairwise comparison (GPC)

Questions and answers during the webinar:  QA – Webinar Benefit from Immunotherapy

Webinar on Assessing Treatment Benefit in Immuno-Oncology

To access the presentation of this on-demand webinar, register to the right

ABSTRACT: 

The management of cancer patients in clinical practice is undergoing a revolution due to the introduction of effective immunotherapy. Several different strategies immuno-oncologycurrently rely on harnessing the immune system to fight tumors, leading to unprecedented therapeutic success. However, immunotherapy has also created the need to revisit the assessment of treatment benefit, possibly because its mechanism of action leads to effects on short- and long-term outcomes in a manner that differs from those of other modalities. For example, clinical trials of immune checkpoint inhibitors have disclosed novel issues related to the assessment of objective responses and have reinstated overall survival as a reliable primary endpoint, often to the detriment of progression-free survival (PFS). Moreover, pseudoprogression has become an issue in some tumor types, and the duration of responses has emerged as a relevant endpoint. In parallel, the limitations of current statistical methods of survival analysis that are based on the proportional-hazards assumption have become more apparent, and novel methods have been proposed.

SPEAKERS

Marc Buyse, ScD, Chief Scientific Officer IDDI

Everardo Saad, MD: Medical Director IDDI.

  • He has over 15 years of experience in Medical Oncology and clinical trial designs.
  • He graduated in Medicine and trained in Internal Medicine in Sao Paulo, and did his fellowship in Medical Oncology at the University of Texas M.D. Anderson Cancer Center, in Houston.
  • After practicing for several years, he shifted his professional career towards education and research in Medical Oncology, and has a special interest in clinical trial methodology, the assessment of endpoints, and the development of novel therapies for cancer patients.
Presentation of the webinar on Assessing Treatment Benefit in Immuno-Oncology

To access the presentation of this on-demand webinar, please fill out this form.

By submitting this form, you agree to receiving commercial electronic messages such as e-mails from IDDI. For more info, please visit our Privacy Policy. You can unsubscribe at any time by clicking the 'unsubscribe' button at the foot of any e-mail communication from IDDI.

I authorize IDDI to use my data to contact me for commercial purposes. More information
Powered by Atypic ®

IDDI